| 125.67 Data as of Jun 18 |  +0.73 / +0.58%Today’s Change | 68.57 Today|||52-Week Range 133.00 | +46.13% Year-to-Date |
| Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner C... Jun 18 / Benzinga | Simcere Ties Up with Bristol-Myers - Analyst Blog Jun 17 / Zacks.com |
| "Pay-For Delay" Was Fun While It Lasted Jun 18 / MotleyFool.com | Label Expansion for Astellas Drug - Analyst Blog Jun 17 / Zacks.com |
| How the Supreme Court Caused Anger With 'Pay to Delay' (ACT) Jun 18 / Benzinga | Actavis Announces Supreme Court Reverse Appeals Ruling in FTC v. Actavis Jun 17 / Benzinga |
| Cramer's Top Stock Picks: RRGB BLMN GCI OPK CCO ACT BGS Jun 18 / TheStreet.com | Actavis-Medicines360 Ink Partnership - Analyst Blog Jun 13 / Zacks.com |
| Cramer's 'Mad Money' Recap: Don't Fear the Fed Jun 17 / TheStreet.com | Why the Pfizer-Teva Settlement Affects the Whole Industy Jun 13 / MotleyFool.com |
| Previous close | 124.94 |
| Today’s open | 125.22 |
| Day’s range | 124.44 - 126.27 |
| Volume | 621,683 |
| Average volume (3 months) | 1,602,635 |
| Market cap | $16.7B |
| Dividend yield | -- |
| Earnings growth (last year) | -63.11% |
| Earnings growth (this year) | +38.47% |
| Earnings growth (next 5 years) | +12.00% |
| Revenue growth (last year) | +29.02% |
| P/E ratio | NM |
| Price/Sales | 1.83 |
| Price/Book | 4.16 |
| Today’s change | Today’s % change | |
|---|---|---|
| VRTXVertex Pharmaceutica... | +0.05 | +0.06% |
| ALXNAlexion Pharmaceutic... | +1.07 | +1.17% |
| ZTSZoetis Inc | +0.22 | +0.71% |
| SHPGShire PLC | -0.03 | -0.03% |
| Next reporting date | July 31, 2013 |
| EPS forecast (this quarter) | $2.00 |
| Annual revenue (last year) | $5.9B |
| Annual profit (last year) | $97.3M |
| Net profit margin | 1.65% |
Sector Health Technology |
Industry Pharmaceuticals: Generic |
President, Chief Executive Officer & Director Paul M. Bisaro |
Global Chief Financial Offi cer R. Todd Joyce, CPA |
Corporate headquarters Parsippany, New Jersey |
.
